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RESEARCH ARTICLE
Red-Shifted Aequorin Variants Incorporating
Non-Canonical Amino Acids: Applications in
In Vivo Imaging
Kristen M. Grinstead1, Laura Rowe2, Charles M. Ensor3, Smita Joel1, Pirouz Daftarian1,
Emre Dikici1, Jean-Marc Zingg1, Sylvia Daunert1*
1 Department of Biochemistry and Molecular Biology, R. Bunn Gautier Bldg., 1011 NW 15th Street, Miller
School of Medicine, University of Miami, Miami, FL, 33136, United States of America, 2 Department of
Chemistry, 1610 Campus Drive East, Valparaiso University, Valparaiso, IN, 46385, United States of America,
3 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY,
40536, United States of America
* SDaunert@med.miami.edu
Abstract
The increased importance of in vivo diagnostics has posed new demands for imaging tech-
nologies. In that regard, there is a need for imaging molecules capable of expanding the
applications of current state-of-the-art imaging in vivo diagnostics. To that end, there is a
desire for new reporter molecules capable of providing strong signals, are non-toxic, and
can be tailored to diagnose or monitor the progression of a number of diseases. Aequorin is
a non-toxic photoprotein that can be used as a sensitive marker for bioluminescence in vivo
imaging. The sensitivity of aequorin is due to the fact that bioluminescence is a rare phe-
nomenon in nature and, therefore, it does not suffer from autofluorescence, which contrib-
utes to background emission. Emission of bioluminescence in the blue-region of the
spectrum by aequorin only occurs when calcium, and its luciferin coelenterazine, are bound
to the protein and trigger a biochemical reaction that results in light generation. It is this reac-
tion that endows aequorin with unique characteristics, making it ideally suited for a number
of applications in bioanalysis and imaging. Herein we report the site-specific incorporation
of non-canonical or non-natural amino acids and several coelenterazine analogues, result-
ing in a catalog of 72 cysteine-free, aequorin variants which expand the potential applica-
tions of these photoproteins by providing several red-shifted mutants better suited to use in
vivo. In vivo studies in mouse models using the transparent tissue of the eye confirmed the
activity of the aequorin variants incorporating L-4-iodophehylalanine and L-4-methoxyphe-
nylalanine after injection into the eye and topical addition of coelenterazine. The signal also
remained localized within the eye. This is the first time that aequorin variants incorporating
non-canonical amino acids have shown to be active in vivo and useful as reporters in biolu-
minescence imaging.
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Introduction
Imaging is a critical component of medical diagnostics and biomedical research. X-Ray com-
puted tomography, ultrasonography, magnetic resonance imaging (MRI), and positron emission
tomography imaging (PET), and optical methods based on fluorescence or bioluminescence are
used as stand-alone or in-tandem in diagnostic imaging to provide information on morphologi-
cal, anatomical, or organ function. Despite their wide use, the majority of these methods do not
have the ability to monitor specific molecular events linked to disease states and provide a com-
plete picture of a biochemical process. In vivo imaging systems (IVIS) [1–4] is currently the
state-of-the-art instrumentation used in molecular imaging to investigate biological processes in
whole animal bioluminescence imaging (BLI) employing reporter technologies. IVIS has a fast
image acquisition time (from seconds to a few minutes) and can be used to image several ani-
mals at once, providing a high throughput cost-effective alternative.
“Living light” or bioluminescence, is a naturally occurring phenomenon where light is gen-
erated by living organisms. Bioluminescence has several advantages over fluorescence, most
notably the high sensitivity shown by the subattomole detection limits in vitro, and low back-
ground caused by the lack of inherent bioluminescence in most tissues [5–8]. Furthermore,
bioluminescence does not require external illumination, making it suitable for light sensitive
organs and tissues such as the retina.
Bioluminescent studies have frequently been conducted using the intracellular expression of
proteins such as firefly luciferase (FLuc) and Renilla luciferase (RLuc) [9–21]. Though these
proteins have the benefits of bioluminescence and have been used for in vivo cell tracking and
gene expression, they require the incorporation of foreign DNA or the transplant of transgenic
tissue [22, 23]. To overcome these drawbacks, we propose the direct administration of engi-
neered red-shifted emission variants of the photoprotein aequorin, a protein employed previ-
ously in deep tissue calcium measurements [24].
Aequorin is a 22 kDa non-toxic photoprotein originally isolated from the bioluminescent
jellyfish Aequorea victoria and employed initially for in vivo calcium detection [25, 26]. In addi-
tion, aequorin has found numerous applications in cell trafficking [27, 28], biosensing [29–32],
and in bioluminescent competitive [30] and immunoassays [33–41]. Aequorin uses the conver-
sion of the incorporated luciferin coelenterazine to coelenteramide to emit a flash of light at
472 nm. The coelenterazine is bracketed in the hydrophobic pocket by H-bonds with three tri-
ads: Tyr184-His169-Trp173, Tyr192-His58-Trp108, and Tyr82-His16-Trp86 [42–44] (Fig 1).
The addition of calcium causes a change in the conformation of the protein, triggering the bio-
luminescence reaction. The availability of different synthetic coelenterazine analogs with a
variety of emission maxima and half-lives, allows for the tuning of emitted light [45, 46]. Since
wild-type aequorin emits in the blue region of the visible spectrum, and since the emitted light
at that particular wavelength is more easily absorbed and scattered by tissue, the availability of
red-shifted aequorin mutants is important for further expanding its role in vivo.
In addition to synthetic coelenterazine, random and site-directed mutations have been used
by us and others to create a variety of aequorin analogs with different wavelengths of emission
and half-lives [8, 46, 48–54]. Although aequorin variants with unique spectral characteristics
using canonical amino acids have been created, the range of emission properties can be further
tailored by strategic incorporation of non-natural amino acids [46, 53].
Previous studies have shown that mutations in the protein sequence involving the Tyr82-
His16-Trp86 triads using canonical amino acids have a great effect on the spectral characteris-
tics of aequorin while maintaining its bioluminescent activity, most notably a red-shift in the
emission wavelength. This led to the selection of the tyrosine at position 82 and tryptophan
at position 86 for replacement in a cysteine-free aequorin variant (hereafter “aequorin“), to
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minimize the absorption of the signal by tissue during in vivo studies, such as in calcium imag-
ing and in the previously mentioned deep tissue studies [41, 55]. In this study, the tryptophan
residue at position 86 was replaced with four different non-natural amino acids L-4-aminophe-
nylalanine (AminoPhe), L-4-bromophenylalanine (BromoPhe), L-4-iodophenylalanine
(IodoPhe), and L-4-methoxyphenylalanine (MethoxyPhe). The position was also substituted
simultaneously with the tyrosine at position 82. The variants were then complexed with native
coelenterazine and eight synthetic coelenterazines cp, f, fcp, h, hcp, i, ip, and n (Fig 2).
To test the applicability of these red-shifted aequorin variants for in vivo imaging the variant
with the greatest red-shifted wavelength and the variant with the longest half-life were each
injected introsomally into the eye of a 6–8 week old ICR (CD1) outbred female mouse. The
Fig 1. Structures of wild-type aequorin and the non-natural amino acid analogs employed for site-selective incorporation into the protein. (A)
Crystal structure of aequorin with the location of the Tyr82-His16-Trp86. The substituted tyrosine is at position 82 and the substituted tryptophan is at
position 86. (B) Chemical structure of non-natural amino acids: L-4-aminophenylalanine, (C) L-4-bromophenylalanine, (D) L-4-iodophenylalanine, (E) L-4
methoxyphenylalanine (PDB ID: 1EJ3). Reprinted from [47]under a CC BY license, with permission fromOpen Access Dissertations, original copyright
2015.
doi:10.1371/journal.pone.0158579.g001
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bioluminescence was then triggered by topical addition of coelenterazine and the emission of
light detected with a IVIS instrument. Though aequorin has been part of imaging tissues as dif-
ficult to access as the deep brain, [56], the eye was chosen for our initial visualization studies
because of its characteristics of optical transparency, simple anatomy, well-defined structure,
and easy accessibility.
Results and Discussion
To circumvent the limitations of current luminescent proteins in imaging and expand their use in
vivo, we have prepared a catalog of mutants of the tunable photoprotein aequorin [8, 26, 46, 57].
We prepared these variants by site-specifically incorporating non-natural amino acids into
selected sites of the hydrophobic pocket of aequorin using Amber Suppression [42, 55, 58, 59].
Previous work in our group employing Amber Suppression replaced a tyrosine residue at position
82 by introducing a TAG codon to create functional non-natural variants of aequorin with red-
shifted wavelengths of emission and longer bioluminescence half-lives [46]. In the present study,
our group individually incorporated four different non-natural amino acids, specifically, L-4-ami-
nophenylalanine (AminoPhe), L-4-bromophenylalanine (BromoPhe), L-4-iodophenylalanine
Fig 2. Structures of synthetic coelenterazines. Reprinted from [47] under a CC BY license, with permission fromOpen Access Dissertations, original
copyright 2015.
doi:10.1371/journal.pone.0158579.g002
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(IodoPhe), and L-4-methoxyphenylalanine (MethoxyPhe), into aequorin at position 86 alone and
82 and 86 together (Fig 1). These non-natural amino acid residues were selected for their hydro-
phobicity, aromaticity, and their size similarity to tyrosine and tryptophan [42–44]. By complex-
ing them with native coelenterazine and eight synthetic coelenterazine analogs, this work resulted
in 72 new bioluminescent aequorin variants; several of these variants had red-shifted wavelengths
of emission, and both shorter and longer bioluminescence half-lives were observed as compared
to those of native aequorin.
Two plasmid systems were developed to express the aequorin variants. The first system
incorporated the non-natural amino acids into position 86 using a pBAD/HisA vector by using
well-established molecular biology protocols [60] that was co-transformed with pDULE vectors
engineered for each non-natural amino acid procured from the Schultz group [61]. This resulted
in a system in which the expression of aequorin is tightly regulated by the araBAD promoter
and protein expression is induced by the addition of arabinose to the culture medium. The cul-
ture was then spun down and aequorin isolated from the supernatant by acid precipitation.
Low-level expression of the L-4-aminophenylalanine aequorin prompted the generation of a
second system in which the aequorin gene with a TAG codon at position 86 was inserted into a
pET30Xa/LIC plasmid. This construct produced a good yield of the 86 variant aequorin and
was used in all subsequent experiments (S1 Fig). The pETXa/LIC also included a His6x tag to
aid in purification.
The protein variants were prepared by supplementing the culture media containing the
appropriate plasmids with the selected non-natural amino acid and expression was induced
with IPTG. The cells were lysed, and the protein variants were isolated and purified using affin-
ity chromatography. Incorporation of the non-natural amino acids was verified by mass spec-
trometry (S1 Table, S7–S11 Tables) and the resulting variants were complexed with one of nine
different coelenterazine analogs: native, cp, f, fcp, h, hcp, i, ip, or n. The resulting aequorin vari-
ants were characterized for specific activity, wavelength emission maximum, and biolumines-
cence emission half-life (S2–S4 Tables). Though not all mutants displayed a marked red-shift
and also displayed the loss in specific activity associated with synthetic coelenterazine analogs,
several mutant aequorin and synthetic coelenterazine complexes showed suitable emission
characteristics.
The data in Table 1 shows the change in the wavelength maximum emission spectra and
bioluminescence emission half-lives for selected variants as well as wild-type aequorin. The
aequorin variants with single substitutions at position 86 showed longer bioluminescence emis-
sion half-lives than those found in our previous study with an aequorin containing a single
Table 1. Emission characteristics of selected aequorin variants.
Aequorin and CTZ Wavelength (nm) Half-life (s)
Wild-type Aequorin and Native 472 0.5
IodoPhe 86 Native 499 14.3
IodoPhe 86 i 508 38.01
AminoPhe 82&86 Native 496 3.57
AminoPhe 82&86 i 515 58.68
BromoPhe 82&86 Native 500 3.21
BromoPhe 82&86 i 514 55.62
IodoPhe 82&86 Native 500 4.19
IodoPhe 82&86 i 508 64.74
MethoxyPhe 82&86 Native 513 3.53
MethoxyPhe 82&86 i 526 48.73
doi:10.1371/journal.pone.0158579.t001
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non-natural incorporation at position 82. Further, the double non-natural incorporation pro-
duces variants with a marked red-shifted wavelength of bioluminescence emission [46]. Most
significantly, aequorin with L-4-methoxyphenylalanine at positions 82 and 86 complexed with
coelenterazine i emits maximal bioluminescence at 526 nm, which is the largest red-shift of
wavelength of any aequorin variant reported thus far and 11 nm longer than the previous most
red-shifted aequorin, namely, L-4-methoxyphenylalanine at position 82 [46]. Fig 3 shows the
interactions of the tryptophan residue at position 86 with the coelenterazine molecule. By
mutating the Trp86, the stability of the phenol ring moiety associated with the Tyr82-His16-
Trp86 triad is affected by the change in the H-bond network. In examining the binding interac-
tions of the amino acids in the binding pocket with the newly prepared variant aequorin with
L-4-aminophenylalanine and L-4- methoxyphenylalanine, it is evident that these non-natural
amino acids, which have an amino group and methoxy group, respectively, are capable of
maintaining a polar interaction with coelenterazine, while L-4-bromophenylalanine and L-
4-iodophenylanine are not. We postulate that the loss of the H-bonds that stabilize the luciferin
could explain the red-shifted emission wavelengths of the halogenated aequorin variants L-
4-bromophenylalanine and L-4-iodophenylanine. Also, the presence of iodine in a molecule
can increase the transition probability of an electron in an excited singlet state to an excited
triplet state, creating a shift in the emission spectra as well as the elongation of the half-life
[62].
While all novel non-natural amino acid-modified aequorin variants show an increase in the
half-lives of the bioluminescence emission, the most notable half-life changes are associated
with the variants containing coelenterazine i. These variants display the longest biolumines-
cence decay half-lives with an average of approximately 1 minute, while the half-life of
aequorin with native coelenterazine is approximately a half second (Table 1). Notably, the
Fig 3. Native coelenterazine in the binding pocket of aequorin. The grey dashed lines represent the Van der Waal surface of the ligand. Green
dashed lines with an arrowhead represent an H-bond going from donor to recipient. The structure is based on aequorin’s crystal structure [43](PDB ID:
1EJ3). Reprinted from [47] under a CC BY license, with permission fromOpen Access Dissertations, original copyright 2015.
doi:10.1371/journal.pone.0158579.g003
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aequorin variant with a double substitution of L-4-iodophenylalanine at positions 82 and 86
paired with coelenterazine i has the longest bioluminescence half-life emission time reported
as well at approximately 60 s, compared to our own previously reported 14 s with a single L-
4-methoxyphenylalanine at position 82 paired with coelenterazine i (Fig 4) [46].
The increased probability of the transition of the excited electron from singlet state to triplet
state due to the heavy atom can explain the differences in half-lives of the coelenterazines that
have iodine compared to the ones that do not possess a heavy atom [62]. This trend is also
present in the modified aequorins with a L-4-bromophenylalanine substitution, though to a
Fig 4. Emission wavelengths and bioluminescence half-lives of selected aequorin variants. (A)
Bioluminescence emission spectra of aequorin with L-4-aminophenylalanine at position 86 with
coelenterazine cp (red), aequorin with native coelenterazine (black), and L-4-methoxyphenylalanine at
position 82 and 86 with coelenterazine i (green), illustrating the range of emission wavelengths in this study.
(B) Half-life bioluminescence decay of aequorin with native coelenterazine (black), L-
4-methoxyphenylalanine with coelenterazine n (orange), and L-4-iodophenylalanine with coelenterazine i
(blue), illustrating the range of emission half-lives in this study. Reprinted from [47] under a CC BY license,
with permission fromOpen Access Dissertations, original copyright 2015.
doi:10.1371/journal.pone.0158579.g004
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lesser extent. Interestingly, in our previous work, the single substitution of Tyr82 did not dis-
play as great an increase in the half-life of the bioluminescence emission as the single substitu-
tion at position Trp86, even with coelenterazine i, but, in contrast, they did exhibit greater red-
shift in emission wavelength. The variants with non-natural amino acid substitutions at both
positions, Tyr82 and Trp86, show a mixed influence of both substitutions, with longer emission
half-lives as well as greater red-shifted emission spectra. These emission characteristics may
allow for multiplex detection by spatial and temporal resolution through the differentiation of
the emission wavelength and time [51].
The feasibility of employing the red-shifted aequorin variants for in vivo imaging was
explored by injecting the photoproteins into the right eyes (intrastromal as well as antecham-
ber) of anesthetized mice, chosen for their easy accessibility and simple anatomy as well as for
the potential to replace fluorescence in eye studies. The variants with L-4-methoxyphenylala-
nine at positions 82 and 86 and L-4-iodophenylalanine at positions 82 and 86 were chosen for
their red-shifted emission wavelength and long bioluminescence half-life, respectively. The left
eyes of the mice were only injected with buffers to serve as internal controls. Additionally, mice
without aequorin injected into either eye were imaged. Fig 5 shows the imaging experiments
performed by intrastromal injection of identical concentrations of aequorin and L-4-methoxy-
phenylalanine variants. Native coelenterazine was added to the surface of the eye dropwise to
turn “on” the light, that is, trigger the emission of the flash of bioluminescence from the photo-
proteins, which was immediately recorded by the IVIS. External addition of calcium ions was
not necessary since the eye already contains an abundance of calcium ions. Fig 5 also shows
bioluminescence emission from the aequorin and the L-4-iodophenylalanine variant injected
into the antechamber of the eye. The L-4-iodophenylalanine variant was added at a greater
concentration due to the lower specific activity exhibited in the in vitro studies (S2 Table). The
mice were observed for up to 1 1/2 hours after the addition of the coelenterazine and still dis-
played bioluminescence, attributed to the time necessary for the coelenterazine to diffuse to the
aequorin. There was also no bioluminescent signal outside of the eye itself, demonstrating that
Fig 5. Bioluminescence emission of selected aequorin variants in an in vivomousemodel.Mice received a 5 μL intrastromal or antechamber
injection in the right eye with variant aequorin and the left eye with HEPES Buffer. (A,B) Aequorin injected intrastromally at a concentration of 2.7 x 10−5 M,
30 s exposure. (C) Aequorin with L-4-methoxyphenylalanine at positions 82 and 86. (D) HEPES Buffer only in both eyes. (E) Aequorin injected in the
antechamber at a concentration of 3.2 x 10−5 M, 60 s exposure. (F) Aequorin with L-4-iodophenylalanine at positions 82 and 86. Images generated with
Matlab R2014b and LivingImage 4.4. Reprinted from [47] under a CC BY license, with permission fromOpen Access Dissertations, original copyright
2015.
doi:10.1371/journal.pone.0158579.g005
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the aequorin did not diffuse to other areas after injection. These results with in vivo imaging
suggest that these red-shifted aequorin variants could also be used for imaging studies in other
tissues or organs in animals in the future. Bioluminescent resonance energy transfer (BRET)
employing aequorin has been demonstrated effective in deep tissue studies, thus suggesting
that the aequorin designed, prepared, and employed herein could potentially be translated to
applications in deeper tissues [63, 64].
Conclusions
In conclusion, our data demonstrate that aequorin variants containing non-natural amino
acids in place of the tryptophan residue at position 86 and the tyrosine at position 82 showed
red-shifted bioluminescence activity when complexed with native coelenterazine. Moreover,
the peak emission wavelengths and half-lives of these variants can further be extended by using
coelenterazine analogs. Though not all the mutants showed a significant shift and displayed a
drop in specific activity associated with coelenterazine analogs, several had shifts beyond 45
nm and were tested in vivo. The aequorin variant with L-4-methoxyphenylalanine at positions
82 and 86 with complexed coelenterazine i displays a Δ56 nm red-shift in bioluminescence
emission wavelength, being 526 nm the greatest red-shift reported thus far for an aequorin var-
iant. Thus, this broadens the realm of applications of aequorin variants as reporter molecules
in multiplex applications and in vivo imaging. These red-shifted aequorin variants showed
excellent performance in imaging experiments when applied to the eye of a mouse, thus dem-
onstrating their potential use in molecular imaging for diagnostics and/or management of
disease. In summary, the red-shifted aequorin variants prepared and reported herein demon-
strated improved characteristics for in vivo imaging with regard to our previously reported
photoproteins, broadening the applications of aequorin in biomedical analysis and diagnostics.
Materials and Methods
Ethics statement
All animal procedures were performed in compliance with the Association for Research and
Vision in Ophthalmology (ARVO) Statement for the use of Animals in Ophthalmic and Vision
Research and in accordance with the Guide for the Care and Use of Laboratory Animals (pro-
tocol 13–034) published by the National Institutes of Health and approved by the Animal Care
and Use Committee of the University of Miami.
Reagents
The pBAD/His A and Terrific Broth (TB) are from Invitrogen (Carlsbad, CA). The PET-30
Xa/LIC Kit and Xa Factor Cleavage Capture Kit are from Novagen (Madison, WI). NcoI and
HindIII restriction endonucleases are from New England Biolabs (Boston, MA). All natural
amino acids, and all antibiotics, are from Sigma-Aldrich (St. Louis, MO). LB agar and LB broth
are from Fischer Scientific (Fair Lawn, NJ). The coelenterazines are from Gold Biotechnology
(St. Louis, MO). The L-4-aminophenylalanine, L-4-bromophenylalanine, L-4-iodophenylala-
nine, and L-4-methoxyphenylalanine are from Peptech (Burlington, MA).
Apparatus
Cells were grown in a Thermo-Fisher Scientific orbital shaker incubator at 37°C. Cell cultures
were harvested using a Beckman J2-MI centrifuge. The proteins were purified using a BioCad
Sprint Perfusion Chromatography System (Perseptive Biosystems, Farmington, MA) using 20
mL DEAEWaters AP-2 Anion Exchange Column (Waters Corporation, Milford, MA). The
Aequorin in In Vivo Imaging
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buffers for the purification of the protein were 30 mM Tris-HCl, pH 7.5, containing 2 mM
EDTA (Buffer A) and 30 mM Tris-HCl, pH 7.5, containing 2 mM EDTA, and 1 M NaCl
(Buffer B). Diafiltration was performed using a tangential flow separation module with hollow
fiber filter membrane (Spectrum Labs, Rancho Dominguez, CA) using 30 mM Tris-HCl, pH
7.5, containing 2 mM EDTA. Ni-NTA Agarose beads are from Qiagen (Venlo, Netherlands).
Amicon Ultra-15 Centrifugal Filter Units are from EMD (Billerica, MA). Purity of the proteins
was confirmed by the appearance of a single band after sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) using a Novex Mini-cell apparatus from Invitrogen and stain-
ing with Coomassie Brilliant Blue. Aequorin activity was measured using an Optocomp I
luminometer (MGM Biomedical Hamden, CT). The emission spectra of the aequorins were
determined using a custom made SpectroScan instrument (ScienceWares, Falmouth, MA),
which is capable of obtaining spectra from flash reactions of luminescent samples that emit in
the 400–700 nm range. Half-life scans were taken using a Polarstar Optimax 96 well microplate
reading luminometer (BMG Labtech, Ortenberg, Germany).
Construction of the pDULE-pBADHisA-AEQTAG86 expression strains
Four pDULE vectors which allow for the site-specific incorporation of four different non-natu-
ral amino acids were obtained from Dr. Peter Schultz (Scripps Research Institute, La Jolla CA)
and Dr. Ryan Mehl (Franklyn and Marshall College, Lancaster, PA) [61]. Each of these pDULE
plasmids coded for a tRNACUA and tRNACUA-synthetase specific for the TAG codon and a
single non-natural amino acid, either L-4-aminophenylalanine, L-4-bromophenylalanine, L-
4-iodophenylalanine, or L-4-methoxyphenylalanine. These plasmids were transformed into
Escherichia coli DH10B cells and transformants were selected by plating on LB agar medium
containing ampicillin (100 μg/mL) and tetracycline (12 μg/mL). The presence of the pDULE
plasmid was confirmed by plasmid isolation, restriction enzyme digestion and DNA gel
electrophoresis.
Construction of the pDULE-pET30AEQ8286TAG expression strains
The four pDULE plasmids were transformed into E. coli DH10B cells with pET30AEQ8286-
TAG and transformants were selected by plating on LB agar medium containing tetracycline
(12 μg/mL) and kanamycin (35 μg/mL). The presence of the pDULE plasmid was confirmed
by plasmid isolation, restriction enzyme digestion and DNA gel electrophoresis.
pBADAEQ86TAG was prepared by inserting the AEQTAG86 gene with the ompA leader
sequence attached into pBAD/HisA. The pIN4AEQ86TAG vector containing the cysteine-free
aequorin gene fused to the ompA leader sequence was used as a template. The primers were
designed so the resulting DNA sequence contained an NcoI site at the 5’ end and a HindIII site
at the 3’ end.
The following primers were used for the cloning of ompA:AEQ86TAG fusion into pBAD/
HisA vector (restriction sites for cloning are underlined).
AEQforpBAD. 5'-CCATGGGTATGAAAAAGACAGCTATCGCGATTGC-3’
AEQrevpBAD. 5'AAGCTTAGGGGACAGCTCCACCGTAGAGCTTTTCGGAAGCAGGATC
CATTGTGTAC-3’
The resulting PCR product was gel purified and cloned into the pCR1II-TOPO1 vector by
using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA). The plasmid from the TA clone
was then isolated and sequenced to confirm the presence of the insert. The ompA:AEQ86TAG
insert from the TOPO TA clone was then ligated into the NcoI and HindIII sites of pBAD/His
A to create pBADHisA-AEQ86TAG.
Aequorin in In Vivo Imaging
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The AEQTAG86 gene was also cloned into a pET30 Xa/LIC Vector using primers designed
according to the manufacturer’s instructions. pET30AEQ8286TAG was then prepared by
using a pair of primers to create a site-specific mutation consisting of a TAG at position 82
(underlined).
Oligo HPLCTAG8286for. 5'-GGAAACTGATTGGCCTGCATAGATTGAAGG-3’
HPLCTAG8286rev. 5'-CCTTCAATCTATGCAGGCCAATCAGTTTCC-3’
pBADHisA-AEQ86TAG and pET30AEQ8286TAG vectors were transformed into chemi-
cally competent E. coli DH10B cells that already contained the pDULE plasmids to produce
four different strains, each specific for the incorporation one of the four non-natural amino
acids mentioned above. Selection for transformants was performed by plating on LB agar
medium containing both ampicillin (100 μg/mL) kanamycin (35 μg/mL) for cells containing
pBADHisA-AEQ86TAG and tetracycline (12 μg/mL) and kanamycin (35 μg/mL) for cells con-
taining pET30AEQ8286TAG.
Expression and isolation of aequorin variants from
pBADHisA-AEQ86TAG
The cells harboring the pDULE systems with pBADHisA-AEQ86TAG vector were grown in 25
mL of LB broth containing ampicillin (100 μg/mL) and tetracycline (12 μg/mL). All cultures,
unless specified otherwise, were grown overnight at 37°C with shaking at 250 rpm. These over-
night cultures were used to inoculate 500 mL of LB broth containing the appropriate antibiotics
and the cultures were grown at 37°C at 250 rpm to an OD600 between 0.4–0.6. The corresponding
non-natural amino acid was then added to a final concentration of 1 mM. The culture was allowed
to grow for 1 hour and then induced with arabinose (0.2% final concentration) overnight.
The culture was centrifuged at 15,300 xg for 20 min and the pellet discarded. The superna-
tant was acid precipitated using 12 M HCl, then spun again. The pellet was resuspended in
Tris-HCl, pH 7.5, containing 2 mM EDTA.
Expression and isolation of aequorin variants from pET30AEQ8286TAG
The cells were grown in 25 mL of Terrific broth (TB) containing tetracycline (12 μg /mL) and
kanamycin (35 μg/mL) overnight at 37°C at 250 rpm. The overnight cultures were used to inoc-
ulate 500 mL of TB broth containing the same antibiotics and the cultures were grown at 37°C
at 250 rpm. After growing to an OD600 between 0.4–0.6, the corresponding non-natural amino
acid was added to a final concentration of 1 mM. The culture was allowed to grow for 1 hour
and then induced with 1 mM IPTG and grown overnight.
The culture was centrifuged at 15,300 xg for 20 min and the pellet was boiled for 5 min in
Native Purification Buffer (50 mMNaH2PO4, 0.5 M NaCl, 1 mM Imidazole, pH = 8.0). The
boiled pellet was centrifuged again and the supernatant added to 1 mL of suspended Ni-NTA
agarose beads and rotated on a Mini Labroller (Labnet, Woodridge, NJ) at room temperature
for 2 hours. The protein was eluted off the column using a PBS Buffer with 20 mM imidazole at
pH = 8.0 and digested with Xa factor according to manufacturer’s instructions until all the His
tag was cleaved from the protein. The Xa factor was removed with Xa factor Agarose capture
beads. The cleaved aequorin was then concentrated using Amicon Ultra spin columns.
Determination of activities of aequorin variants
Aequorin was diluted with 30 mM Tris-HCl, pH 7.5, containing 2 mM EDTA, to 1x10-7 M and
charged with 1x10-4 M coelenterazine overnight. Aequorin activity was triggered by injecting
100 μL of 100 mM Tris-HCl, pH 7.5, containing 100 mM CaCl2. Bioluminescence intensity
was measured at 0.1 s intervals for up to 6 s on an Optocomp I luminometer (MGM
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Biomedical Hamden, CT). Units are in Relative Light Units (RLU) per mole. N = 3 or more,
standard deviation is 5% or less.
Emission spectra of aequorin variants
A 1 x 10−6 M sample of each aequorin was charged by incubating overnight at 4°C with 1x10-4
M of each of the different coelenterazines and 150 μL of each charged aequorin was pipetted
into a 96-well microtiter plate and following injection of 100 μL of 100 mM Tris-HCl, pH 7.5,
containing 100 mM CaCl2, the emission spectra was collected for 10 s over a scanning range of
400–700 nm in 1.5 nm increments on a custom made SpectroScan instrument (ScienceWares,
Falmouth, MA). N = 3 or more, standard deviation is 5% or less.
Half-life determination of aequorin variants
A 1x10-6 M sample of each aequorin variant was charged overnight at 4°C with the 1x10-4 M of
the coelenterazine analogue used during the collection of emission spectra. A Polarstar Opti-
max 96 well microplate luminometer (BMG Labtech, Ortenberg, Germany) was utilized for the
half-life measurements. Filters were not required. The bioluminescence signal of a 50 μL sam-
ple was collected between 30 s to 150 s, depending on the expected half-life of the aequorin
analogue, following the injection of 100 μL of triggering buffer (100 mM Tris-HCl, pH 7.5, con-
taining 100 mM CaCl2). The mean bioluminescence decay spectra was fit with an exponential
decay equation using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA), and an equa-
tion for first order decay kinetics was used to calculate the bioluminescence half-life of each
aequorin-coelenterazine pair. N = 3 or more, standard deviation is 5% or less.
Mass spectrometry
Proteins were run on SDS-PAGE and cut out of the stained gels with Coomassie Blue. Gel
pieces were digested with trypsin, and an LC-ESI-MS-MS was performed using a ThermoFin-
nigan LTQ. Resulting MS-MS spectra were compared with proteins in the Swiss-Prot database
using the X!Tandem search engine to look for the presence of the substitution of the non-natu-
ral amino acid at and only at the target positions.
In vivo imaging
The aequorin variants were dissolved in a HEPES Buffer (10 mMHEPES, 0.15 M NaCl at
pH = 7.4) at concentrations from 9.1 x 10−6 M to 4.5 x 10−5 M. All mice were anesthetized with
a 100 μL ketamine/xylazine (1.5 mg/0.3 mg) by intraperitoneal injection before the injection of
the sample. The aequorin samples were injected into one eye of six mice via intrastromal injec-
tion in 5 μL volumes, or into the antechamber at a volume of 10 μL, of each of the ICR (CD1)
outbred female mice (6–8 weeks old, purchased from Taconic (Germantown, NY)). The same
volumes of plain HEPES were injected into the other eye to serve as an internal control. Native
coelenterazine was diluted in PBS buffer to a volume of 2.3 x 10−4 M and dropped onto the
surface of each eye in 1 μL volumes. The mice were then placed in a Caliper/Xenogen IVIS1
SPECTRUM (Caliper, Hopkinton, MA) in the IVIS Small Animal Imaging Facility at the
Oncogenmonics Core Facility, Miller School of Medicine, with oxygen flowing into the imag-
ing chamber. Images were taken over 30 s to 60 s.
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